Novel 3,3′-diindolylmethane derivatives: Synthesis and cytotoxicity, structural characterization in solid state

European Journal of Medicinal Chemistry

Volumn 44, Issue 10, 2009, Pages 4136-4147

  Maciejewska, Dorota ^a   Rasztawicka, Magdalena ^a   Wolska, Irena ^b   Anuszewska, Elzbieta ^c   Gruber, Beata ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

3,3 Dindolylmethane derivatives; 13C CP MAS NMR; Cytotoxicity; X ray diffraction

Indexed keywords

3,3' DIINDOLYLMETHANE; 4,4' DIMETHOXY 3,3' DIINDOLYLMETHANE; 5,5' DIETHOXY 3,3' DIINDOLYLMETHANE; 5,5' DINITRO 3,3' DIINDOLYLMETHANE; BENZENE; BROMINE DERIVATIVE; FLUORINE DERIVATIVE; INDOLE; IODINE DERIVATIVE; NITRO DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MELANOMA CELL; SOLID STATE; X RAY DIFFRACTION;

ANTICARCINOGENIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; HUMANS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MELANOMA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; X-RAY DIFFRACTION;

EID: 67651152580     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.05.011     Document Type: Article

References (38)

1. Dashwood R.H., Fong A.T., Williams D.E., Hendricks J.D., and Bailey G.S. Cancer Res. 51 (1991) 2362-2365
2. Kim D.J., Han B.S., Ahn B., Hasegawa R., Shirai T., Ito N., and Tsuda H. Carcinogenesis 18 (1997) 377-381
3. De Kruif C.A., Marsman J.W., Venekamp J.C., et al. Chem. Biol. Interact. 80 (1991) 305-315
4. Chen I., McDougal A., Wang F., and Safe S. Carcinogenesis 19 (1998) 1631-1639
5. Chang X., Tou J.C., Hong C., et al. Carcinogenesis 26 (2005) 771-778
6. Nachshon-Kedmi M., Fares F.A., and Yannai S. Prostate 61 (2004) 153-160
7. Hong C., Kim H.A., Firestone G.L., et al. Carcinogenesis 23 (2002) 1297-1305
8. Hong C., Firestone G.L., and Bjeldanes L.F. Biochem. Pharmacol. 63 (2002) 1085-1097
9. Xue L., Firestone G.L., and Bjeldanes L.F. Oncogene 24 (2005) 2343-2353
10. Gong Y., Sohn H., Xue L., Firestone G.L., and Bjendales L.F. Cancer Res. 66 (2006) 4880-4887
11. M.A. Zeligs, C. Jacobs, Formulation and Use of Controlled Release Indole Alkaloids, US Patent 6,416,793; 9.07.2002.
12. Shirani H., Stensland B., Bergman J., and Janosik T. Synlett 15 (2006) 2459
13. Shirani H., and Janosik T. Synthesis 17 (2007) 2690
14. McDougal A., Gupta M.S., Ramamoorthy K., Sun G., and Safe S.H. Cancer Lett. 151 (2000) 169
15. Pradhan P.K., Dey S., Giri V.S., and Jaisankar P. Synthesis (2005) 1779-1782
16. Földeak S., Czombos J., and Matkowics B. Acta Univ. Sjeged. Acta Phys. Chem. 11 (1965) 115-125
17. Pal C., Dey S., Mahato S.K., Vinayagam J., Pradhan P.K., Giri V.S., Jaisankar P., Hossain T., Baruri S., Ray D., and Biswas S.M. Bioorg. Med. Chem. Lett. 17 (2007) 4924-4928
18. Ji S.J., Wang S.Y., Zhang Y., and Loh T.P. Tetrahedron 60 (2004) 2051-2055
19. Nagarajan R., and Perumal P.T. Chem. Lett. 33 (2004) 288-289
20. Haleblian J., and McCrane W. J. Pharm. Sci. 58 (1969) 911-929
21. Apperley D.C., Fletton R.A., Harris R.K., Lancaster R.W., Tavener S., and Threlfall T.L. J. Pharm. Sci. 88 (1999) 1275
22. Bauer-Brandl A. Int. J. Pharm. 140 (1996) 195
23. Harris R.H. J. Pharm. Pharmacol. 59 (2007) 225-239
24. Maciejewska D., Niemyjska M., Wolska I., Włostowski M., and Rasztawicka M. Z. Naturforsch. 59b (2004) 1137-1142
25. Rasztawicka M., Wolska I., and Maciejewska D. J. Mol. Struct. 831 (2007) 174-179
26. Macrae C.F., Edgington P.R., McCabe P., Pidcock E., Shields G.P., Taylor R., Towler M., and van de Streek J. Mercury: visualization and analysis of crystal structures. J. Appl. Crystallogr. 39 (2006) 453
27. Maciejewska D., Wolska I., Niemyjska M., and Żero P. J. Mol. Struct. 753 (2005) 53-60
28. HyperChem 7.01 (2002), Hypercube Inc., Canada
29. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Montgomery Jr. J.A., Vreven T., Kudin K.N., Burant J.C., Millam J.M., Iyengar S.S., Tomasi J., Barone V., Mennucci B., Cossi M., Scalmani G., Rega N., Petersson G.A., Nakatsuji H., Hada M., Ehara M., Toyota K., Fukuda R., Hasegawa J., Ishida M., Nakajima T., Honda Y., Kitao O., Nakai H., Klene M., Li X., Knox J.E., Hratchian H.P., Cross J.B., Adamo C., Jaramillo J., Gomperts R., Stratmann R.E., Yazyev O., Austin A.J., Cammi R., Pomelli C., Ochterski J.W., Ayala P.Y., Morokuma K., Voth G.A., Salvador P., Dannenberg J.J., Zakrzewski V.G., Dapprich S., Daniels A.D., Strain M.C., Farkas O., Malick D.K., Rabuck A.D., Raghavachari K., Foresman J.B., Ortiz J.V., Cui Q., Baboul A.G., Clifford S., Cioslowski J., Stefanov B.B., Liu G., Liashenko A., Piskorz P., Komaromi I., Martin R.L., Fox D.J., Keith T., Al-Laham M.A., Peng C.Y., Nanayakkara A., Challacombe M., Gill P.M.W., Johnson B., Chen W., Wong M.W., Gonzalez C., and Pople J.A. Gaussian 03, Revision B.02 (2003), Gaussian, Inc., Pittsburgh, PA
30. Pindur U., and Witzel H. Monatsh. Chem. 121 (1990) 77-80
31. Oxford Diffraction Poland, CrysAlisCCD, CCD Data Collection GUI, Version 1.171.31.8 (2007) and 1.171.32.5 (2007).
32. Oxford Diffraction Poland, CrysAlisRED, CCD Data Reduction GUI, Version 1.171.31.5 (2006) and 1.171.32.5 (2007).
33. Sheldrick G.M. Acta Crystallogr. A46 (1990) 467-473
34. Sheldrick G.M. SHELXL97, Program for the Refinement of Crystal Structures (1997), University of Göttingen, Germany
35. Anuszewska E.L., Gruber B.M., and Koziorowska J.H. Biochem. Pharmacol. 54 (1997) 597-603
36. Anuszewska E.L., and Koziorowska J.H. Mutat. Res. 431 (1999) 25-30
37. Mosmann T. J. Immunol. Methods 65 (1983) 55-60
38. Gruber B.M., and Anuszewska E.L. Toxicol. In Vitro 16 (2002) 663-667